Skip to main content
Top
Published in: BMC Public Health 1/2010

Open Access 01-12-2010 | Correspondence

Hormone Replacement Therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain

Authors: Elisa Chilet-Rosell, Marta Martín-Llaguno, María Teresa Ruiz-Cantero, Pablo Alonso-Coello

Published in: BMC Public Health | Issue 1/2010

Login to get access

Abstract

Background

The balance of the benefits and risks of long term use of hormone replacement therapy (HRT) have been a matter of debate for decades. In Europe, HRT requires medical prescription and its advertising is only permitted when aimed at health professionals (direct to consumer advertising is allowed in some non European countries). The objective of this study is to analyse the appropriateness and quality of Internet advertising about HRT in Spain.

Methods

A search was carried out on the Internet (January 2009) using the eight best-selling HRT drugs in Spain. The brand name of each drug was entered into Google's search engine. The web sites appearing on the first page of results and the corresponding companies were analysed using the European Code of Good Practice as the reference point.

Results

Five corporate web pages: none of them included bibliographic references or measures to ensure that the advertising was only accessible by health professionals. Regarding non-corporate web pages (n = 27): 41% did not include the company name or address, 44% made no distinction between patient and health professional information, 7% contained bibliographic references, 26% provided unspecific information for the use of HRT for osteoporosis and 19% included menstrual cycle regulation or boosting feminity as an indication. Two online pharmacies sold HRT drugs which could be bought online in Spain, did not include the name or contact details of the registered company, nor did they stipulate the need for a medical prescription or differentiate between patient and health professional information.

Conclusions

Even though pharmaceutical companies have committed themselves to compliance with codes of good practice, deficiencies were observed regarding the identification, information and promotion of HRT medications on their web pages. Unaffected by legislation, non-corporate web pages are an ideal place for indirect HRT advertising, but they often contain misleading information. HRT can be bought online from Spain, without a medical consultation or prescription constituting a serious issue for public health. In our information society, it is the right and obligation of public health bodies to ensure that such information is not misleading.
Appendix
Available only for authorised users
Literature
1.
go back to reference Krieger N, Löwy I, Aronowitz R, Bigby J, et al: Hormone replacement therapy, cancer, controversies and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health. 2005, 59: 740-48. 10.1136/jech.2005.033316.CrossRefPubMedPubMedCentral Krieger N, Löwy I, Aronowitz R, Bigby J, et al: Hormone replacement therapy, cancer, controversies and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health. 2005, 59: 740-48. 10.1136/jech.2005.033316.CrossRefPubMedPubMedCentral
2.
go back to reference Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef
3.
go back to reference Grady D, Applegate W, Bush TL, Furberg C, Riggs B, Hulley S: Heart and Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics. Control Clin Trials. 1998, 19: 314-35. 10.1016/S0197-2456(98)00010-5.CrossRefPubMed Grady D, Applegate W, Bush TL, Furberg C, Riggs B, Hulley S: Heart and Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics. Control Clin Trials. 1998, 19: 314-35. 10.1016/S0197-2456(98)00010-5.CrossRefPubMed
4.
go back to reference Chilibeck PD: Exercise and Estrogen or Estrogen Alternatives (Phytoestrogens, Biphosphonates) for Prevention of Bone Mineral in Postmenopausal Women. Canadian Journal of Applied Physiology. 2004, 29: 59-75. 10.1139/h04-006.CrossRefPubMed Chilibeck PD: Exercise and Estrogen or Estrogen Alternatives (Phytoestrogens, Biphosphonates) for Prevention of Bone Mineral in Postmenopausal Women. Canadian Journal of Applied Physiology. 2004, 29: 59-75. 10.1139/h04-006.CrossRefPubMed
6.
go back to reference International Menopause Society: HRT in the early menopause: scientific evidence and common perceptions. Summary of the first IMS Global Summit on menopause-related issues. Climateric. 2008, 11: 267-272. 10.1080/13697130802226866.CrossRef International Menopause Society: HRT in the early menopause: scientific evidence and common perceptions. Summary of the first IMS Global Summit on menopause-related issues. Climateric. 2008, 11: 267-272. 10.1080/13697130802226866.CrossRef
9.
go back to reference Castillo Pérez P: Promoción y publicidad farmacéutica: Quo Vadis?. Med Clin (Barc). 1992, 99: 305-09. Castillo Pérez P: Promoción y publicidad farmacéutica: Quo Vadis?. Med Clin (Barc). 1992, 99: 305-09.
11.
go back to reference European Commission: Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions - eEurope 2002: Quality Criteria for Health related Websites. /* COM/2002/0667 final */ European Commission: Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions - eEurope 2002: Quality Criteria for Health related Websites. /* COM/2002/0667 final */
12.
go back to reference European Federation of Pharmaceutical Industry Associations: Code on the Promotion of Prescription-Only Medicines to, and interactions with, healthcare professionals. 1990, Brussels: EPFIA European Federation of Pharmaceutical Industry Associations: Code on the Promotion of Prescription-Only Medicines to, and interactions with, healthcare professionals. 1990, Brussels: EPFIA
19.
go back to reference Mintzes B: Disease Mongering in drug promotion: do governments have a regulatory role?. Plos Med. 2006, 3 (4): 461-5. 10.1371/journal.pmed.0030198.CrossRef Mintzes B: Disease Mongering in drug promotion: do governments have a regulatory role?. Plos Med. 2006, 3 (4): 461-5. 10.1371/journal.pmed.0030198.CrossRef
20.
go back to reference Moynihan R, Heath I, Henry D: Selling sickness: the pharmaceutical industry and disease mongering. Br Med J. 2002, 324: 886-91. 10.1136/bmj.324.7342.886.CrossRef Moynihan R, Heath I, Henry D: Selling sickness: the pharmaceutical industry and disease mongering. Br Med J. 2002, 324: 886-91. 10.1136/bmj.324.7342.886.CrossRef
21.
go back to reference Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R: Drugs for pre-osteoporosis: prevention or disease mongering?. BMJ. 2008, 336 (7636): 126-9. 10.1136/bmj.39435.656250.AD.CrossRefPubMedPubMedCentral Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R: Drugs for pre-osteoporosis: prevention or disease mongering?. BMJ. 2008, 336 (7636): 126-9. 10.1136/bmj.39435.656250.AD.CrossRefPubMedPubMedCentral
23.
go back to reference Muir Gray JA: Canadian clinicians and patients need clean, clear knowledge. CMAJ. 2004, 175: 129-CrossRef Muir Gray JA: Canadian clinicians and patients need clean, clear knowledge. CMAJ. 2004, 175: 129-CrossRef
Metadata
Title
Hormone Replacement Therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain
Authors
Elisa Chilet-Rosell
Marta Martín-Llaguno
María Teresa Ruiz-Cantero
Pablo Alonso-Coello
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2010
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-10-134

Other articles of this Issue 1/2010

BMC Public Health 1/2010 Go to the issue